Determination of Buccal Mucosal Absorption: In Vitro Permeation Testing for Oral Cavity Products

Buccal mucosal absorption determination is a specialized in vitro permeation test that quantifies how much of an active ingredient or chemical substance penetrates through the oral cheek mucosa and becomes systemically available. Performed in accredited third-party laboratories using Franz diffusion cells and excised porcine buccal tissue, the method supports safety assessment of oral care products, buccal drug delivery development, and regulatory submissions. This article explains the technical principles, sample types, measured parameters, testing procedures, and practical applications of the method.

Technical Overview

Buccal mucosal absorption determination (also referred to as oral mucosal permeation testing) measures the quantity of a test substance that diffuses through the stratified squamous epithelium lining the inner cheek and reaches the receptor compartment of a diffusion cell. The buccal route is physiologically significant because the oral mucosa is thin, highly vascularized, and partially bypasses hepatic first-pass metabolism, meaning that substances retained in the oral cavity can produce meaningful systemic exposure.

The test is typically conducted by accredited third-party laboratories using vertical static Franz diffusion cells or flow-through diffusion cells loaded with excised porcine buccal mucosa. The general experimental framework follows the principles of OECD Test Guideline 428 (in vitro skin absorption) and its associated guidance document, adapted to the temperature, thickness, and non-keratinized structure of oral mucosa. For materials that contact mucous membranes as part of medical devices, the test complements the biological evaluation framework of the ISO 10993 series. For cosmetic oral care products, results feed directly into systemic exposure calculations consistent with the safety assessment approach recommended by the Scientific Committee on Consumer Safety (SCCS).

Key variables controlled during the study include membrane source and thickness, receptor fluid composition, temperature, dose level, exposure duration, and analytical quantification. The output is a permeation profile from which steady-state flux, cumulative absorption, and mucosal retention are derived.

Testing Samples

Oral Care Cosmetic Products

Toothpastes, mouthwashes, oral sprays, whitening gels and strips, breath fresheners, and oral rinses are tested to estimate systemic exposure to active or preservative ingredients during normal use. The applied dose is designed to reflect realistic consumer exposure concentrations and contact times.

Buccal and Sublingual Pharmaceutical Dosage Forms

Buccal tablets, mucoadhesive films and patches, lozenges, medicated chewing gums, and buccal sprays are evaluated during formulation development to compare release and permeation performance, screen absorption enhancers, and support in vitro–in vivo correlation studies.

Nicotine-Containing and Tobacco-Related Products

Nicotine pouches, snus-type products, and dissolvable tobacco formats are tested to characterize mucosal transfer of nicotine and other constituents, providing supporting data for exposure assessments.

Food-Contact and Ingestible Ingredients

Flavoring agents, high-intensity sweeteners, colorants, and functional ingredients intended for prolonged oral residence can be assessed for mucosal uptake.

Dental Materials and Oral Medical Devices

Extracts or leachables from denture adhesives, dental cements, fillings, and mucoadhesive devices may be evaluated for mucosal permeation as part of biocompatibility characterization aligned with ISO 10993 principles.

Testing Items

The following quantitative endpoints are typically reported for a buccal permeation study:

• Cumulative permeation amount (Q, expressed in μg/cm²) at each sampling time point and at the end of exposure
• Steady-state permeation flux (Jss, μg/cm²·h), obtained from the linear region of the cumulative permeation curve
• Permeability coefficient (Kp, cm/h), calculated as Jss divided by the donor concentration under infinite-dose conditions
• Lag time (Tlag, h), determined from the x-intercept of the steady-state regression line
• Percentage of applied dose permeated (%), supporting mass-based exposure estimates
• Mucosal tissue retention (μg/g tissue or μg/cm²), representing substance deposited within the epithelium
• Donor residue and receptor recovery, enabling full mass balance verification (typical acceptance range 85–115%)
• Membrane integrity indicators, such as transepithelial electrical resistance (TEER) or permeation of a marker compound such as caffeine or fluorescein sodium

Testing Methods

Membrane Selection and Preparation

Excised porcine buccal mucosa is the preferred model because its epithelial thickness, lipid composition, and non-keratinized structure closely resemble human buccal tissue. Fresh or controlled-frozen mucosa is obtained from inspected slaughterhouse material, separated from underlying muscle and connective tissue, and trimmed to a uniform thickness (commonly 500–800 μm). Each membrane is inspected visually, measured, and mounted between the donor and receptor chambers with the epithelial surface facing the donor side.

Diffusion Cell Configuration

Vertical static Franz diffusion cells with a diffusion area of approximately 1–2 cm² and a receptor volume of 5–12 mL are most common; flow-through cells are used when continuous receptor renewal is required. The receptor fluid is typically phosphate-buffered saline (PBS) at pH 7.4, with mild solubilizers or low concentrations of surfactant added when needed to maintain sink conditions for lipophilic test substances.

Test Conditions

• Temperature: 37 ± 1 °C in the water-jacketed cell bodies, approximating oral cavity temperature
• Stirring: continuous magnetic stirring of the receptor fluid (approximately 350–600 rpm) to eliminate boundary layers
• Equilibration: 15–30 minutes of pre-equilibration followed by membrane integrity verification before dosing
• Dose application: a finite, use-realistic dose for exposure simulation, or an infinite dose for mechanistic flux and Kp determination

Sampling Schedule and Duration

Receptor fluid aliquots are withdrawn at predetermined intervals, for example 0.5, 1, 2, 4, 6, and 8 hours, with immediate replacement by fresh pre-warmed medium to maintain constant volume. Because excised buccal epithelium progressively loses barrier viability, exposure durations are typically capped at 4–8 hours, shorter than the 24-hour protocol used for skin in OECD TG 428.

Analytical Quantification

Permeated amounts are quantified using validated instrumental methods appropriate to the analyte, including HPLC with UV or fluorescence detection, LC-MS/MS for trace-level and multicomponent analysis, and GC-MS for volatile or semi-volatile substances. Calibration curves, quality control samples, and blank membrane controls are included in each analytical batch.

Data Treatment and Quality Assurance

Cumulative permeation is corrected for sampling dilution and plotted against time. Steady-state flux is derived by linear regression, lag time from the x-intercept, and the permeability coefficient from the ratio of flux to donor concentration. At the end of exposure, the mucosa is rinsed, digested, and analyzed to determine tissue retention, completing the mass balance. Studies are performed with a minimum of three replicate cells per condition, reference control compounds, and documented acceptance criteria for integrity, recovery, and analytical precision.

Applications

Buccal mucosal absorption data serve multiple technical and regulatory purposes:

• Cosmetic safety assessment: permeation-derived flux values are converted into systemic exposure dose and combined with toxicological reference values to calculate the margin of safety for ingredients in oral care products
• Pharmaceutical formulation development: ranking candidate buccal formulations, mucoadhesive polymers, and penetration enhancers according to permeation performance before clinical studies
• Exposure characterization for nicotine and oral tobacco alternatives, supporting product stewardship and regulatory documentation
• Biocompatibility support for dental materials and oral medical devices that release substances onto mucosal surfaces
• Research applications: mechanistic studies of epithelial transport, barrier modeling, and in vitro–in vivo correlation development
• Regulatory dossiers: providing standardized, reproducible permeation evidence acceptable in safety files and technical documentation submitted to competent authorities

FAQ

Why is porcine buccal mucosa the standard test membrane?

Porcine buccal mucosa is anatomically and biochemically similar to human buccal epithelium in thickness, keratinization status, and lipid barrier organization. It is widely available from inspected food-industry sources, which avoids the scarcity and ethical constraints associated with human oral tissue, while offering reproducible barrier properties.

How does buccal permeation testing differ from skin permeation testing?

Buccal mucosa is non-keratinized and lacks the stratum corneum, making it generally more permeable than skin. Test temperatures reflect the oral cavity rather than skin surface, exposure durations are shorter to preserve tissue viability, and receptor conditions are tuned to simulate saliva-contacted surfaces rather than air-exposed skin.

How long does a typical study take?

The in vitro permeation phase usually runs 4–8 hours with serial sampling, while complete studies including membrane preparation, analytical method validation, sample analysis, and reporting are typically completed within several weeks depending on the analytical complexity.

What happens if the test substance is poorly water-soluble?

Receptor fluids are modified with qualified solubilizers or low-level surfactants to maintain sink conditions without damaging the membrane. Pre-formulation assessment confirms donor-phase compatibility, and mass-balance checks ensure that low recovery reflects true retention rather than analytical loss.

How are the results used in risk assessment?

Can human buccal tissue be used?

Human tissue can be used when ethically sourced surgical residue is available and appropriate consent and approvals are in place. Because availability is limited, porcine tissue remains the practical reference model, and human tissue is generally reserved for confirmation studies.